Sunday , August 18 2019
Home / argentina / Chile will provide tablets to prevent the spread of HIV. NEWS | Industry

Chile will provide tablets to prevent the spread of HIV. NEWS | Industry

The Chile government announced last Friday free delivery with preventive pills before administration (PrEP), a drug that prevents the transmission of HIV; during first quarter of 2019

To this end, the Chilean authorities, a country that doubled the number of infected people in the past seven years, met with members The movement of homosexual integration and liberation (Movilh), to define protocols regulating its use next year.

"PrEP pills can reduce the risk of acquiring a virus by over 90% during sexual practices if it is taken every dayThat is why there must be a protocol that will lead people to real effects and encourage them to favor safe sexual practices because it is not the idea that the pill causes relaxation, "said Diego Ríos, director of the Movilh health area.

According to the Minister of Health Emilio Santelices, the PrEP pill is part of a new plan against AIDS and HIV and will be used as a preventative treatment in high-risk populations.

How it's working?

According to Centers for Disease Control and Prevention in the United States (CDC), if PrEP is taken daily, you get reduced by over 90% the chance of contracting a virus that causes AIDS by sex or 70% using needles that are not sterilized or used by many people.

PrEP contains emtricitabine and tenofovir, two medicines that are also used in antiretroviral medicines because they reduce the amount of virus in the blood and prevent it from multiplying.

The tablets do not act as vaccines, because they do not generate antibodies, but rather that their daily intake is necessary so that emtricitabine and tenofovir are present in the blood at the time of infection and prevent the build-up of HIV in the body.

Before its consumption it is necessary to check the correct state of the kidneys and liver, because the pill can cause disorders in these organs.

More information

It was the American pharmaceutical company Gilead Sciences that began marketing the drug in 2012 under the brand name TruvadaIt is estimated that the commercial value of the monthly treatment reaches $ 600.

Many years later, the World Health Organization (WHO) began to recommend its use to prevent HIV infection among high-risk groups such as sex workers or couples of infected patients.


According to Onusida data for 2017, Chile has 67,000 people infected with HIV, of which 39,131 are under treatment, and projections indicate an increase in the number of people affected by HIV to 100,000 by the end of this year.

Source link